To promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
USA115th CongressHR-2212| House
| Updated: 4/28/2017
Tom Marino
Republican Representative
Pennsylvania
Cosponsors (25)
Bob Gibbs (Republican)Marcy Kaptur (Democratic)Mark Meadows (Republican)Peter T. King (Republican)David N. Cicilline (Democratic)John Abney Culberson (Republican)Carol Shea-Porter (Democratic)Steve Cohen (Democratic)Peter A. DeFazio (Democratic)Todd Rokita (Republican)James B. Renacci (Republican)Andy Barr (Republican)Glenn Grothman (Republican)Eleanor Holmes Norton (Democratic)Mike Gallagher (Republican)Daniel Lipinski (Democratic)Jamie Raskin (Democratic)Dave Brat (Republican)Janice D. Schakowsky (Democratic)Beto O'Rourke (Democratic)Peter Welch (Democratic)Bennie G. Thompson (Democratic)John J. Duncan (Republican)Lloyd Doggett (Democratic)Francis Rooney (Republican)
Health Subcommittee, Judiciary Committee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Creating and Restoring Equal Access To Equivalent Samples Act of 2017 or the CREATES Act of 2017 This bill permits the developer of a drug or biological product to bring a civil action against the license holder of an approved drug or biological product if the holder has declined to make available sufficient quantities of the approved drug or product for the developer's testing.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Health
Civil actions and liabilityDrug safety, medical device, and laboratory regulationLicensing and registrationsPrescription drugsProduct development and innovation
To promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
USA115th CongressHR-2212| House
| Updated: 4/28/2017
Creating and Restoring Equal Access To Equivalent Samples Act of 2017 or the CREATES Act of 2017 This bill permits the developer of a drug or biological product to bring a civil action against the license holder of an approved drug or biological product if the holder has declined to make available sufficient quantities of the approved drug or product for the developer's testing.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Tom Marino
Republican Representative
Pennsylvania
Cosponsors (25)
Bob Gibbs (Republican)Marcy Kaptur (Democratic)Mark Meadows (Republican)Peter T. King (Republican)David N. Cicilline (Democratic)John Abney Culberson (Republican)Carol Shea-Porter (Democratic)Steve Cohen (Democratic)Peter A. DeFazio (Democratic)Todd Rokita (Republican)James B. Renacci (Republican)Andy Barr (Republican)Glenn Grothman (Republican)Eleanor Holmes Norton (Democratic)Mike Gallagher (Republican)Daniel Lipinski (Democratic)Jamie Raskin (Democratic)Dave Brat (Republican)Janice D. Schakowsky (Democratic)Beto O'Rourke (Democratic)Peter Welch (Democratic)Bennie G. Thompson (Democratic)John J. Duncan (Republican)Lloyd Doggett (Democratic)Francis Rooney (Republican)
Health Subcommittee, Judiciary Committee, Energy and Commerce Committee
Health
Related Bills
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Civil actions and liabilityDrug safety, medical device, and laboratory regulationLicensing and registrationsPrescription drugsProduct development and innovation